Qualigen Therapeutics (NASDAQ:QLGN) versus Unicycive Therapeutics (NASDAQ:UNCY) Head-To-Head Analysis

Unicycive Therapeutics (NASDAQ:UNCY) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Earnings & Valuation

This table compares Unicycive Therapeutics and Qualigen Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680,000.00	173.66	-$36.73 million	($3.95)	-1.39
Qualigen Therapeutics	N/A	N/A	-$6.26 million	($7.50)	-0.38

Qualigen Therapeutics has lower revenue, but higher earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Unicycive Therapeutics has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Unicycive Therapeutics and Qualigen Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1	0	3	0	2.50
Qualigen Therapeutics	1	0	0	0	1.00

Unicycive Therapeutics currently has a consensus price target of $34.33, suggesting a potential upside of 524.81%. Given Unicycive Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Unicycive Therapeutics is more favorable than Qualigen Therapeutics.

Profitability

This table compares Unicycive Therapeutics and Qualigen Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-227.32%	-117.71%
Qualigen Therapeutics	N/A	N/A	-202.16%

Institutional & Insider Ownership

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 10.7% of Unicycive Therapeutics shares are held by insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Unicycive Therapeutics beats Qualigen Therapeutics on 9 of the 12 factors compared between the two stocks.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.